Article

Technology in trials: Early results promising for presbyopia reversal

Orlando-Early results from a clinical trial for the reversal and treatment of presbyopia, using SurgiLight Inc.'s OptiVision technology, appear "promising," according to researchers at New York-Presbyterian Hospital Weill Cornell Medical Center.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
Related Content
Navigate successful cataract surgery with refractive technology
July 11th 2025

Navigate successful cataract surgery with refractive technology

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients
July 10th 2025

Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair
July 10th 2025

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

PulseSight doses first patient in PST-611-CT1
July 9th 2025

PulseSight doses first patient in PST-611-CT1

© 2025 MJH Life Sciences

All rights reserved.